After a median follow-up of 17.5 years, the 20-year freedom from progression (FFP) was 90% vs 65% for aC3high vs aC3low patients (p<0.0001)….In a large study with extremely long follow-up, aC3high HRS cell expression was associated with superior FFP after ABVD or equivalent regimens.